For the quarter ending 2026-03-31, RKDA made $1,100K in revenue. -$4,385K in net income. Net profit margin of -398.64%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 1,100 | 901 | 1,302 | - |
| Cost of revenues | 700 | 708 | 884 | - |
| Research and development | - | 0* | 0 | - |
| Gain on sale of intangible assets | 0 | 0 | 0 | - |
| Impairment of property and equipment | - | 0* | 0 | - |
| Change in fair value of contingent consideration | 0 | 0 | 0 | - |
| Selling, general and administrative | 1,179 | 1,570 | 1,570 | - |
| Total operating expenses | 1,879 | 2,278 | 2,454 | - |
| (loss) income from continuing operations | -779 | -1,377 | -1,152 | - |
| Interest income | 5 | -2 | 7 | - |
| Credit gain | - | 1,380* | -257 | - |
| Other gain, net | -1,504 | -1,844* | 1,698 | - |
| Loss on january 2026 inducement offer | -2,877 | - | - | - |
| Change in fair value of common stock warrant and option liabilities | 1,191 | 510 | 560 | - |
| Net loss from continuing operations before income taxes | - | -1,334* | - | - |
| Income tax expense | - | 2* | - | - |
| Net loss from continuing operations | - | -1,336 | 856 | - |
| Net loss from discontinued operations | - | 0 | 0 | - |
| Issuance and offering costs | 421 | - | - | - |
| Net (loss) income from continuing operations | -4,385 | -1,336 | 856 | -4,458 |
| Unrealized gains on available-for-sale securities | - | - | - | 0 |
| Reclassification adjustment for gains on available-for-sale securities included in net (loss) income | - | - | - | 0 |
| Change in unrealized gains on available-for-sale securities | - | - | - | 0 |
| Comprehensive (loss) income | - | - | - | -4,458 |
| Basic EPS | -2.11 | -0.974 | 0.63 | -3.26 |
| Diluted EPS | -2.11 | -0.977 | 0.62 | -3.26 |
| Basic Average Shares | 2,082,887 | 1,371,936 | 1,367,192 | 1,367,040 |
| Diluted Average Shares | 2,082,887 | 1,367,106 | 1,371,879 | 1,367,040 |
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)